Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.25
−$0.05 · -3.85%
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
Latest quote
$1.25
−$0.05 · -3.85%
After-hours
$1.25
$0.00 · 0.00%
Oct 8, 4:10 PM ET
Regular session · ET · Market data may be delayed.
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
Day range
Current $1.25
52-week range
Current $1.25
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
49
Fair Value
Sentiment
54
Mixed
Risk
66
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
Day range
Current $1.25
52-week range
Current $1.25
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 1.83B USD | 5.4M USD | 6.04M USD | 4.75M USD | 2.03M USD |
| Selling, general, and administrative | 6.26B USD | 8.7M USD | 8.53M USD | 7.34M USD | 10.78M USD |
| Operating expenses | 8.09M USD | 14.1M USD | 14.58M USD | 12.09M USD | 12.81M USD |
| Interest income | 125.45K USD | — | — | — | — |
| Depreciation and amortization | — | 14.12M USD | — | — | — |
| Operating income | −8.09M USD | −14.1M USD | −14.58M USD | −12.09M USD | −12.81M USD |
| Net income | −7.97M USD | −14.1M USD | −14.58M USD | −12.09M USD | −12.75M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 3 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 5, 2025 | 1:20 | — | — |
Effective Aug 5, 2025
1:20
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
